FindTrial
Sign In

Simmitinib

DRUG3 trials

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Shanghai Runshi Pharmaceutical Technology Co., Ltd

Conditions

Advanced Oesophageal Squamous Cell CarcinomaAdvanced Solid Tumor

Phase 1

A Phase I Trial of Simmitinib in Advanced Solid Tumors
NCT04058587
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Solid Tumor
Start: 2020-06-08End: 2023-03-31Target: 50Updated: 2022-06-06
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
Not yet recruitingNCT06132217
Shanghai Runshi Pharmaceutical Technology Co., LtdAdvanced Solid Tumor
Start: 2024-01-30End: 2027-01-30Target: 168Updated: 2023-11-15

Phase 3

A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma
Not yet recruitingNCT06656091
Shanghai Runshi Pharmaceutical Technology Co., LtdAdvanced Oesophageal Squamous Cell Carcinoma
Start: 2024-10-31End: 2027-01-30Target: 450Updated: 2024-10-24

Related Papers

First-in-human study of simmitinib, a novel tyrosine kinase inhibitor targeting FGFR1-3, KDR and CSF-1R.
Journal of Clinical Oncology2024-06-01